Gradiant Achieves Strong Growth Across Asia in Cleantech Water Treatment during the Pandemic

– Gradiant demonstrated strong growth during the prolonged COVID-19 pandemic– Gradiant won 26 new projects in 2021 YTD across the Asia Pacific region– Contract wins are in cleantech water treatment solutions with new clients, applications, markets, and geographies, including long-term DBOOM concession agreements– Since the onset of the pandemic, Gradiant has secured 56 new projects […]

New treatment option for schizophrenia Reagila(R) listed on PBS

MELBOURNE, Sep 6, 2021 – (ACN Newswire via – A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for […]

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)

TOKYO, Jul 30, 2021 – (JCN Newswire via – Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) — granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021 — following 18 months of treatment […]

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

TOKYO, Jul 27, 2021 – (JCN Newswire via – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer’s disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer’s Association […]

Central Global Bhd Signs MoU for JV to Build RM250M Kwasa Damansara Sewage Treatment Plant

KUALA LUMPUR, Jun 9, 2021 – (ACN Newswire via – Main Market-listed Central Global Berhad’s (“CGB) construction arm, Proventus Bina Sdn Bhd (“PBSB”), has signed a Memorandum of Understanding (“MoU”) to explore a proposed joint venture (“JV”) with Multi Scopes Sdn Bhd (“MSSB”) for a sewage treatment plant in Selangor. CGB executive chairman Dato’ […]

MHIEC Supplies Incinerators for First Waste-to-Energy Plant in Xiaogan, Hubei Province, China

TOKYO, Apr 27, 2021 – (JCN Newswire via – Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has delivered two state-of-the-art stoker furnaces* for a large-scale waste-to-energy (WtE) plant in Xiaogan, Hubei Province, China. This facility has capacity to process approximately 1,500 tonnes of […]

Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China – First Glucokinase Activator (GKA) Globally

SHANGHAI, CHINA, Apr 23, 2021 – (ACN Newswire via – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). Dorzagliatin is the first glucokinase activator (GKA) to submit […]

Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound

Guangzhou, China, Dec 23, 2020 – (ACN Newswire) – ‘LeSoleil’, a naturally active compound, was discovered as a therapeutic candidate for use against COVID-19. As the new coronavirus began to spread globally, Suntrap Life Technologies Ltd established a special research team. The project, “Research on Anti-New Coronavirus (COVID-19) Prevention Products”, was launched in an emergency […]

NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

SHELTON, CT / ACCESSWIRE, Sep 16, 2020 – (ACN Newswire) – NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program […]

Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China

Beijing and Shanghai, China, Aug 17, 2020 – (ACN Newswire) – Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. The agreement aims to provide Chinese diabetes patients with access to a new treatment option, building on Bayer’s […]

Lifequest subsidiary Biopipe Global enters the United States with Shipment of its Revolutionary 100% Sludge-Free Biological Onsite Sewage Wastewater Treatment Plant to California

RIDGEFIELD PARK, NJ / CHENNAI, IN, Jul 9, 2020 – (ACN Newswire) – via NEWMEDIAWIRE — LIFEQUEST WORLD CORP (LQWC) subsidiary Biopipe Global, which has developed the world’s only highly scalable onsite sludge and chemical-free sewage wastewater treatment technology, has shipped its first plant to California. With a capacity of 10m3/day (2,640 gallons/day), the plant […]

Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin

SHANGHAI, CHINA, Jul 1, 2020 – (ACN Newswire) – Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. All subjects are treated with metformin (Glucophage) at […]

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial

SHANGHAI, CHINA, Jun 18, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin. Dorzagliatin is a first-in-class glucokinase activator […]